Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

NCT03166215 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda

Collaborators